Cerbios-Pharma brings its ADCs technology to DCAT 2018


Cerbios-Pharma brings its ADCs technology to DCAT 2018


Cerbios150x38

Press Release | Cerbios-Pharma SA

FEBRUARY 28, 2018

Lugano, Switzerland: – Swiss-based high-potency API specialist Cerbios-Pharma SA (Cerbios) is returning to the high prestige DCAT Week in New York to showcase its new pipeline of Generic APIs and its exclusive contract development and manufacturing (CDMO) services.

Cerbios will present the full range of its innovative offers that include the fully integrated Antibody Drug Conjugate (ADC) services for the manufacturing of ADCs’ toxins, payloads and conjugation. Cerbios has also further expanded its technologies for CDMO services for “ultra high” potent active ingredients (HPAIs) and for cGMP SCF-atomization particle engineering generating micro and nanoparticle APIs with very narrow particle size distribution. It will also display the products’ pipeline based on the AKVANO® delivery system developed by its participated partner Lipidor: “The AKVANO ® technology allows innovative topical formulations of a wide variety of APIs for several pharmacological applications” said Gabriel Haering, Cerbios CEO.

Specialist teams

Cerbios has been a DCAT member since 2010 and has become an established presence at the event. Cerbios has emailed all its contacts with a direct link that enables them to set up fact to face meetings at DCAT.

The team led by Annalisa Miracca will discuss marketing, sales and product portfolios, while Business Development managers Simone Sala and Matteo Piazza focus on CDMO and exclusive manufacturing services.

Cerbios CEO, Dr. Gabriel Haering, CCO Denis Angioletti and CSO Claudio Pozzoli will also be on hand to discuss strategic alliances and co-operation.

PROVEO™ Alliance

“We are looking forward to returning to New York for this strategic event,” said Cerbios-Pharma Chief Commercial Officer, Denis Angioletti.

“Once again, DCAT Week will provide us with a unique opportunity to deliver in-depth presentations of our innovative API Portfolio and exclusive manufacturing services for HPAIs, mAbs, recombinant proteins and fully integrated ADCs services through the PROVEO™ Alliance,” commented Mr. Angioletti.

“Our ADC manufacturing capabilities are boosted by synergies between our Chemical and Biological divisions and turned into a fully integrated service thanks to our alliance with fellow PROVEO partners,” he explained.

About Cerbios-Pharma

Cerbios-Pharma SA is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners worldwide. Cerbios specializes in the development and production of high potency active pharmaceutical ingredients (HPAPIs) in the area of fine chemicals and biologicals.

Cerbios Chemical Division offers exclusive, third party manufacturing services for HPAIs while Biological Division produces monoclonal antibodies, recombinant proteins and pharma probiotics.

Cerbios provides full CMC support to its worldwide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.

Since 2015, Cerbios has been a member of the ADC manufacture PROVEO™ consortium, forged with AGC Biologics together with Germany’s Oncotec. PROVEO ™ can offer a one-stop shop service from substance development through to full finish.

About DCAT Week 2018

The Drug, Chemical & Associated Technologies Association (DCAT), founded in 1890, has become North America’s premier business development association for companies that manufacture, distribute or provide services to the pharmaceutical and chemical industries.

DCAT represents the entire spectrum of the pharmaceutical industry—from pharmaceutical, API, and excipient sales and manufacturing to distribution, support technologies and packaging products and services.

Attended by thousands of industry professionals, DCAT Week® and the DCAT Annual Dinner, held each March in New York City, are considered one of the pharma industry’s premier events.

DCAT Week 2018 will take place over four days from March 19 to March 22. Renovation at Waldorf Astoria has meant that the event’s traditional headquarters is unavailable this year, with activities shared between seven other downtown hotels including the Lotte New York Palace, Omni Berkshire Place, 48LEX, Benjamin and InterContinental Barclay, with the 91st DCAT Annual Dinner held in the Grand Ballroom of the New York Hilton on Thursday, March 22.

The event is organized by DCAT with more information at: https://www.dcat.org/.

Media Contact

Chiara Brusadelli, Commercial Operations Assistant Manager, Cerbios-Pharma SA
Email: chiara.brusadelli@cerbios.ch
Tel: +41 91 985 6311

Resources

Click on Cerbios-Pharma at DCAT 2018 for more information.
Click on Cerbios-Pharma to contact the company directly.
Click on Contact Form to email request for a DCAT meeting.

Cerbios offers a range of advanced ADC, modified antibodies and other manufacturing services

Cerbios offers a range of advanced ADC, modified antibodies and other manufacturing services

Cerbios CEO Dr. Gabriel Haering

Cerbios CEO Dr. Gabriel Haering


Supplier Information
Supplier: Cerbios-Pharma SA
Address: Via Figino 6, 6917 Barbengo/Lugano Switzerland
Tel: +41 (0) 919856311
Fax: +41 (0) 919856325
Website: www.cerbios.ch


Comments are closed.